Weekly Research Analysts’ Ratings Updates for Cidara Therapeutics (CDTX)

Several analysts have recently updated their ratings and price targets for Cidara Therapeutics (NASDAQ: CDTX):

• 3/12/2025 – Cidara Therapeutics is now covered by analysts at Citigroup Inc.. They set an “outperform” rating on the stock.
• 3/12/2025 – Cidara Therapeutics was given a new $46.00 price target on by analysts at JMP Securities.
• 3/12/2025 – Cidara Therapeutics is now covered by analysts at Citizens Jmp. They set an “outperform” rating and a $46.00 price target on the stock.
• 3/10/2025 – Cidara Therapeutics had its price target raised by analysts at HC Wainwright from $24.00 to $35.00. They now have a “buy” rating on the stock.
• 3/7/2025 – Cidara Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock.
• 2/5/2025 – Cidara Therapeutics was upgraded by analysts at Cantor Fitzgerald to a “strong-buy” rating.
• 1/27/2025 – Cidara Therapeutics had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald.

Cidara Therapeutics Price Performance

Shares of NASDAQ:CDTX traded down $1.60 on Tuesday, reaching $22.03. 210,562 shares of the company traded hands, compared to its average volume of 65,871. The stock has a market capitalization of $241.29 million, a PE ratio of -0.86 and a beta of 0.88. The company’s 50 day moving average is $21.84 and its 200-day moving average is $18.30. Cidara Therapeutics, Inc. has a fifty-two week low of $10.00 and a fifty-two week high of $28.42.

Cidara Therapeutics (NASDAQ:CDTX) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($5.38) EPS for the quarter, missing the consensus estimate of ($5.28) by ($0.10). Cidara Therapeutics had a negative return on equity of 69.64% and a negative net margin of 289.05%. As a group, analysts expect that Cidara Therapeutics, Inc. will post -8.74 EPS for the current year.

Insider Buying and Selling

In related news, insider Leslie Tari sold 1,773 shares of the stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $21.96, for a total transaction of $38,935.08. Following the completion of the sale, the insider now owns 16,215 shares in the company, valued at $356,081.40. This represents a 9.86 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Shane Ward sold 1,664 shares of Cidara Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $21.96, for a total value of $36,541.44. Following the sale, the chief operating officer now directly owns 14,674 shares in the company, valued at $322,241.04. The trade was a 10.18 % decrease in their position. The disclosure for this sale can be found here. 7.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Cidara Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of CDTX. Point72 Asia Singapore Pte. Ltd. acquired a new position in Cidara Therapeutics in the fourth quarter worth $56,000. Point72 Asset Management L.P. bought a new position in shares of Cidara Therapeutics in the fourth quarter worth about $165,000. OMERS ADMINISTRATION Corp acquired a new position in shares of Cidara Therapeutics during the fourth quarter worth approximately $339,000. Jane Street Group LLC bought a new stake in shares of Cidara Therapeutics during the fourth quarter valued at approximately $342,000. Finally, Boothbay Fund Management LLC bought a new position in Cidara Therapeutics in the 4th quarter worth approximately $419,000. 35.82% of the stock is owned by institutional investors and hedge funds.

Cidara Therapeutics, Inc, a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates.